Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 27 apr 2015 - 22:17

Statutaire naam Galapagos NV

Titel Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trial

Bericht ACR20 scores up to 73% as once-daily monotherapy at 12 weeks Statistically significant ACR20 and ACR50 responses at all dose levels Onset of efficacy within first week of treatment in this trial Safety profile in DARWIN 2 consistent with previous filgotinib RA studies Webcast presentation of the results to be held on 28 April 2015, 16.00 CET/10 AM EDT/ 8 AM PDT, +32 2 620 0138, access code 6206795, more call number info further down

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201504270000000013_Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trial.pdf (opens in a new window)

201504270000000013_Filgotinib behaalt ook als monotherapie het primaire eindpunt in de DARWIN 2 reumatoïde artritis studie.pdf (opens in a new window)

Datum laatste update: 20 december 2025